Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Small Cell Lung Cancer

Small Cell Lung Cancer

Part of Extensive-Stage Small-Cell Lung Cancer

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Small Cell Lung Cancer

61 trials tracked for Small Cell Lung Cancer: 8 in phase 3 or 4 and 7 with published results. The most-cited published study has 129 citations.

61Trials tracked
8Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 3 8 Phase 2 47 Phase 1 3 Other / NA 3
  1. Phase 3 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Completed · 129 cited
  2. Phase 3 Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 122 cited
  3. Phase 3 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Completed · 119 cited
  4. Phase 3 Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Completed · 118 cited
  5. Phase 3 A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Completed · 101 cited
  6. Phase 3 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Completed · 42 cited
Show 44 more trials
  1. Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Completed · 35 cited
  2. Phase 3 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed
  3. Phase 2 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Completed
  4. Phase 2 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer Completed
  5. Phase 2 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed
  6. Phase 2 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Completed
  7. Phase 2 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Completed
  8. Phase 2 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Completed
  9. Phase 2 Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Completed
  10. Phase 2 Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Completed
  11. Phase 2 Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer Completed
  12. Phase 2 A Study for Participants With Small-Cell Lung Cancer Completed
  13. Phase 2 Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Completed
  14. Phase 2 Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer Completed
  15. Phase 2 BMS-986012 in Relapsed/Refractory SCLC Completed
  16. Phase 2 Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer Completed
  17. Phase 2 First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin Completed
  18. Phase 2 Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer Completed
  19. Phase 2 Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer Completed
  20. Phase 2 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Completed
  21. Phase 2 Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer Completed
  22. Phase 2 Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma Completed
  23. Phase 2 Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer Completed
  24. Phase 2 Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Completed
  25. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  26. Phase 2 Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Completed
  27. Phase 2 Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Completed
  28. Phase 2 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Completed
  29. Phase 2 Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy Completed
  30. Phase 2 Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma Completed
  31. Phase 2 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Completed
  32. Phase 2 A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) Completed
  33. Phase 2 A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Completed
  34. Phase 2 Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer Completed
  35. Phase 2 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Completed
  36. Phase 2 Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC Completed
  37. Phase 2 SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy Completed
  38. Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. Completed
  39. Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Completed
  40. Phase 2 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) Completed
  41. Phase 2 Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer Completed
  42. Phase 2 Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Completed
  43. Phase 2 Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) Completed
  44. Phase 2 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
Pulmonology & Critical Care Phase II
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.
Apr 6, 2026
Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC
Pulmonology & Critical Care Phase I
Phase I study finds amrubicin-cisplatin with radiotherapy feasible in limited-stage SCLC Small study tests new drug combination with radiation for limited-stage small cell lung cancer
A Phase I dose-finding trial in 9 treatment-naïve patients with limited-stage small cell lung cancer established amrubicin 25 mg/m² plus cis…
A new drug combination with radiation showed a 100% response rate and 64.8% five-year survival in early-stage small cell lung cancer patient…
Apr 5, 2026

Research across Extensive-Stage Small-Cell Lung Cancer

Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.

Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
Drug Pipeline Meta-analysis
Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients Tumor DNA Levels Help Predict Outcomes in Lung Cancer Treatment
This meta-analysis of 2,107 patients evaluates the role of circulating tumor DNA (ctDNA) as a biomarker for outcomes in advanced NSCLC treat…
Testing for circulating tumor DNA may help doctors predict how well patients with advanced lung cancer respond to immunotherapy treatments.
Frontiers Jun 13, 2026
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Hematology Sys. Review
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Frontiers Jun 10, 2026
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Pulmonology & Critical Care RCT
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Jun 7, 2026
Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
Oncology Meta-analysis
Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients Sublobar resection shows mixed survival results for early lung cancer
This umbrella review of meta-analyses indicates sublobar resection carries higher risks for overall and disease-free survival in Stage I non…
An umbrella review found mixed survival results for sublobar resection versus lobectomy in early-stage non-small cell lung cancer.
Frontiers Jun 7, 2026
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Pulmonology & Critical Care Meta-analysis
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
Jun 5, 2026
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
Pulmonology & Critical Care Meta-analysis
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Jun 4, 2026
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Oncology Phase I
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study. Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Jun 4, 2026
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
Pulmonology & Critical Care Meta-analysis
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile Immunotherapy before lung cancer surgery is safe, study finds
This meta-analysis of patients with resectable non-small cell lung cancer found that neoadjuvant or perioperative immune checkpoint inhibito…
A new analysis of 2,691 patients shows that immunotherapy before lung cancer surgery is feasible, but comes with specific surgical challenge…
Jun 1, 2026
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Pulmonology & Critical Care Meta-analysis
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Jun 1, 2026
Perspective review on radiation therapy and cardiac toxicity in lung cancer
Oncology Sys. Review
Perspective review on radiation therapy and cardiac toxicity in lung cancer Radiation planning may help protect heart and immune system in lung cancer patients
This perspective review article synthesizes evidence on thoracic radiation therapy for locally advanced non-small cell lung cancer, focusing…
A perspective review suggests radiation planning techniques could spare the heart and immune system for lung cancer patients.
Frontiers May 28, 2026
Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
Allergy & Immunology Guideline
Observational study links ADAM9 expression to survival in lung adenocarcinoma patients High ADAM9 levels linked to worse lung cancer survival in new data
This research article is an observational study with in vitro experiments analyzing TCGA-LUAD datasets from 517 tumor and 59 normal tissues.…
High ADAM9 expression linked to immunosuppression and poorer survival in lung adenocarcinoma patients based on tissue data and lab experimen…
Frontiers May 25, 2026
Review of Non-small cell lung cancer without reported intervention or outcomes
Oncology Sys. Review
Review of Non-small cell lung cancer without reported intervention or outcomes Review of treatments for non-small cell lung cancer patients
This narrative review addresses non-small cell lung cancer in patients without reporting specific interventions, comparators, or outcomes. T…
This review looks at options for non-small cell lung cancer patients. It gathers what we know about care for this serious illness.
Frontiers May 23, 2026

Questions about Small Cell Lung Cancer

Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?

Yes, a phase II trial found toripalimab plus anlotinib maintenance after first-line chemo led to median progression-free survival of 8.18 months and overall survival of 23.05 months in ES-SCLC.

Full answer →
Do bispecific antibodies or CAR T-cell therapy treat advanced Small Cell Lung Cancer?

Yes, both bispecific antibodies and CAR T-cell therapy are being studied for advanced SCLC, with bispecific antibodies showing more clinical progress, especially tarlatamab targeting DLL3.

Full answer →
Do immune checkpoint inhibitors improve survival for first-line Small Cell Lung Cancer treatment?

Yes, immune checkpoint inhibitors combined with chemotherapy improve survival as first-line treatment for extensive-stage small-cell lung cancer.

Full answer →